Skip to main content

Table 1 Baseline characteristics of patients before and after propensity score matching

From: Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection

Variable

Before matching, No. (%)

After Matching, No. (%)

Untreated group

Treated group*

P value

Untreated group

Treated group*

P value

Number of patients

212,820

18,365

 

18,365

18,365

 

Age, mean (SD), years

49.45 (10.36)

47.82 (9.53)

 

48.00 (9.70)

47.82 (9.53)

 

Age group, years

  

< 0.001

  

0.9995

 30–40, n (%)

48,238 (22.67)

4,534 (24.69)

 

4,532 (24.68)

4,534 (24.69)

 

 41–50, n (%)

61,017 (28.67)

6,242 (33.99)

 

6,233 (33.94)

6,242 (33.99)

 

 51–60, n (%)

69,253 (32.54)

5,786 (31.51)

 

5,794 (31.55)

5,786 (31.51)

 

 60–70, n (%)

34,312 (16.12)

1,803 (9.82)

 

1,806 (9.83)

1,803 (9.87)

 

Male sex, n (%)

112,116 (52.68)

11,158 (60.76)

< 0.001

11,161 (60.77)

11,158 (60.76)

0.9744

Socioeconomic status, n (%)

  

< 0.001

  

0.9960

 Household income > 75, n (%)

82,882 (38.94)

7,279 (39.64)

 

7,271 (39.59)

7,279 (39.64)

 

 Household income 25–75, n (%)

80,210 (37.69)

7,114 (38.74)

 

7,116 (38.75)

7,114 (38.74)

 

 Household income < 25, n (%)

43,680 (20.52)

3,475 (18.92)

 

3,487 (18.99)

3,475 (18.92)

 

 Unknown

6,048 (2.84)

497 (2.71)

 

491 (2.67)

497 (2.71)

 

Level of health care, n (%)

  

< 0.001

  

0.9530

 Tertiary, n (%)

55,088 (25.88)

6,688 (36.42)

 

6,670 (36.32)

6,688 (36.42)

 

 Secondary, n (%)

101,416 (47.65)

8,604 (46.85)

 

8,601 (46.83)

8,604 (46.85)

 

 Primary, n (%)

56,316 (26.46)

3,073 (16.73)

 

3,094 (16.85)

3,073 (16.73)

 

Cirrhosis, n (%)

15,249 (7.17)

5,586 (30.42)

< 0.001

5,577 (30.37)

5,586 (30.42)

0.9187

Preexisting comorbidity

      

 Diabetes mellitus, n (%)

51,679 (24.28)

3,447 (18.77)

< 0.001

3,436 (18.71)

3,447 (18.77)

0.8831

 Hypertension, n (%)

60,415 (38.39)

4,018 (21.88)

< 0.001

3,996 (21.76)

4,018 (21.88)

0.7811

 Dyslipidemia, n (%)

103,031 (48.41)

7,644 (41.62)

< 0.001

7,646 (41.63)

7,644 (41.62)

0.9831

 Chronic kidney disease, n (%)

2,754 (1.29)

103 (0.56)

< 0.001

92 (0.5)

103 (0.56)

0.4296

 Congestive heart failure, n (%)

2,936 (1.38)

157 (0.85)

< 0.001

146 (0.79)

157 (0.85)

0.5257

 Ischemic heart disease, n (%)

14,449 (6.79)

840 (4.57)

< 0.001

812 (4.42)

840 (4.57)

0.4809

 Traumatic brain injury, n (%)

2,092 (0.98)

136 (0.74)

0.0013

116 (0.63)

136 (0.74)

0.2061

  1. Abbreviations: SD, standard deviation
  2. *The type of newly initiated nucleos(t)ide analogue therapy was as follows: tenofovir disoproxil 66.6%, entecavir 22.3%, and other NUCs 11.2%